📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
214 analysed today
FollowTelegram
214
Today
152,076
All-time analysed
43,619
Positive
6,746
Negative
92,864
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
SBI Card Appoints Amit Batra as EVP & Chief Strategy Officer Effective July 2026
SBI Cards and Payment Services has announced the appointment of Mr. Amit Batra as Executive Vice President & Chief Strategy Officer, effective July 01, 2026. Mr. Batra brings approximately 30 years of leadership experience in strategy, operations, and business transformation. He joins from TransUnion CIBIL India, where he served as Chief Operating Officer, and has prior experience with GE Capital and a previous stint at SBI Card. This appointment is aimed at strengthening the company's strategic planning and operational resilience.
Key Highlights
Mr. Amit Batra appointed as EVP & Chief Strategy Officer with effect from July 01, 2026
Possesses approximately 30 years of experience in leadership roles across strategy, ESG, and operations
Previously served as Chief Operating Officer at TransUnion CIBIL India leading enterprise transformation
Alumnus of INSEAD and a Master Black Belt in Lean Six Sigma with past experience at GE Capital and SBI Card
👀 What to Watch
Investors should view this as a positive leadership reinforcement given Mr. Batra's deep background in credit bureau operations and strategy. No immediate action is required as the appointment is effective from July 2026.
Tasty Bite Appoints Rahul Bhatnagar as Chairman Effective April 1, 2026
Tasty Bite Eatables Limited has appointed Mr. Rahul Bhatnagar as the Chairman and Non-Executive Independent Director, effective April 1, 2026. Mr. Bhatnagar is a seasoned executive with over 40 years of experience in FMCG and telecom, having held senior roles at Bharti Enterprises, PepsiCo, and Seagram. He previously managed a portfolio generating $1.2 billion in revenue as Managing Director and CFO at Bharti Enterprises. This appointment brings high-caliber leadership and deep industry expertise to the board.
Key Highlights
Mr. Rahul Bhatnagar appointed as Chairman and Non-Executive Independent Director effective April 1, 2026
Brings over 40 years of experience across FMCG, telecommunications, and consulting sectors
Previously served as MD and CFO at Bharti Enterprises, managing a $1.2 billion revenue portfolio
Educational background includes being a Chartered Accountant and an MBA from Wharton
👀 What to Watch
Investors should view this leadership transition positively due to Mr. Bhatnagar's extensive FMCG experience. No immediate action is required, but monitor for potential strategic shifts under his guidance.
Ambika Cotton Mills Promoters Declare Zero Encumbrance on 50.35% Stake
Promoters of Ambika Cotton Mills Limited have officially declared that there are no encumbrances or pledges on their shareholding as of April 2026. The promoter group, consisting of Sri P.V. Chandran and Smt. C. Bhavani, collectively holds 2,882,350 shares, representing 50.35% of the company's total equity. Specifically, Sri P.V. Chandran holds 10.65% while Smt. C. Bhavani holds 39.70%. This disclosure, filed under SEBI SAST Regulations, confirms that the promoters have not used their equity as collateral for loans.
Key Highlights
Promoters confirm zero encumbrance on their entire 50.35% equity stake
Sri P.V. Chandran holds 6,09,784 shares (10.65% of total equity)
Smt. C. Bhavani holds 22,72,566 shares (39.70% of total equity)
Total promoter group holding stands at 28,82,350 shares out of 57,25,000 total shares
👀 What to Watch
The absence of pledged shares is a positive indicator of promoter financial health and reduces the risk of forced selling. Investors can maintain their positions as this reinforces the company's stable ownership structure.
SBI Life Shareholders Approve Material Related Party Transactions with Over 97% Majority
SBI Life Insurance has successfully obtained shareholder approval for material related party transactions (RPTs) with its parent, State Bank of India, and other group entities including SBI DFHI and SBI Capital Markets. All four ordinary resolutions were passed with a significant majority, exceeding 97% of the votes cast in each case. The voting, conducted via postal ballot ending March 30, 2026, also included approval for transactions with Yes Bank Limited. This ensures operational continuity and maintains the strategic business relationship within the SBI ecosystem.
Key Highlights
Approval for Material Related Party Transactions with State Bank of India passed with 97.81% votes in favor.
Transactions with SBI DFHI Limited and SBI Capital Markets Limited both received 97.84% approval from voting members.
The resolution for transactions with Yes Bank Limited was approved with 97.84% of the total 369.67 million votes polled.
Remote e-voting saw participation from institutional and non-institutional investors, with promoters being interested parties in the resolutions.
👀 What to Watch
No immediate action is required as these approvals are standard for maintaining business synergies with the parent bank. Investors should continue to monitor the volume of these transactions in annual disclosures to ensure they remain at arm's length.
Panacea Biotec Receives ₹22.88 Cr GST Demand; High Court Issues Interim Stay
Panacea Biotec has received a demand order for ₹22.88 crore from the CGST authorities, which includes a principal tax amount of ₹11.44 crore and an equivalent penalty. The dispute pertains to the alleged non-payment of GST on corporate guarantees totaling ₹864 crore issued between April 2019 and March 2022. Crucially, the company has already obtained an interim stay from the Punjab & Haryana High Court, protecting it from coercive recovery actions. The management maintains that the demand is not legally maintainable and is taking steps to contest the order.
Key Highlights
Total demand of ₹22.88 crore comprising ₹11.44 crore GST and ₹11.44 crore penalty.
Dispute relates to corporate guarantees worth ₹864 crore provided over a period of 1,074 days.
Interim stay order granted by Punjab & Haryana High Court prevents coercive action by authorities.
Company filed its response to the Show Cause Notice on March 27, 2026, and considers the demand non-maintainable.
👀 What to Watch
Investors should monitor the final outcome of the writ petition in the High Court as it will determine if the ₹22.88 crore liability materializes. While the stay order mitigates immediate cash flow risks, the legal uncertainty remains a factor for the company's valuation.
MobiKwik Partners with Rajasthan Royals as Official Payments Partner for IPL 2026
One MobiKwik Systems Limited has entered its first-ever major sports partnership, becoming the Official Payments Partner for Rajasthan Royals for the IPL 2026 season. This strategic move is aimed at reaching the next 100 million digital payment users by leveraging the IPL's massive viewership. The partnership will promote MobiKwik's UPI, Personal Loans, and Bill Payment services through co-branded marketing and in-app integrations. As of December 2025, MobiKwik holds an 18% market share in the PPI wallet segment and serves over 186.6 million registered users.
Key Highlights
Designated as the Official Payments Partner for Rajasthan Royals for the IPL 2026 season.
Aims to leverage a user base of 186.6 million+ registered users and 4.79 million+ merchants.
Company holds an 18% market share of PPI wallet Gross Transaction Value (GTV) as of Dec 2025.
Partnership includes digital and in-app integrations for UPI and instant Personal Loans.
Strategic focus on capturing 'young, aspirational India' to drive higher transaction volumes.
👀 What to Watch
Investors should watch for an uptick in user acquisition and loan disbursement volumes following the IPL season to justify the marketing spend. This move indicates an aggressive growth strategy to consolidate market share in the competitive fintech space.
IFB Industries Appoints Veteran Arup Das as Executive Director Effective March 28, 2026
IFB Industries has appointed Mr. Arup Das as an Executive Director on its Board, effective March 28, 2026. Mr. Das is a company veteran who has been with IFB since 1992 and currently serves as President of M&A and New Projects. This appointment is for an interim period until a new Chief Executive Officer or Managing Director is officially appointed. His 38 years of experience across engineering, supply chain, and marketing is expected to provide leadership stability during this transition.
Key Highlights
Mr. Arup Das appointed as Executive Director effective March 28, 2026.
The appointee has over 38 years of total experience, with 34 years dedicated to IFB Industries.
Appointment serves as an interim measure until a permanent CEO or Managing Director is selected.
Mr. Das previously held leadership roles in Engineering, Heat Treatment, and Supply Chain divisions.
The Board meeting for this approval commenced at 11:30 a.m. and concluded at 3:00 p.m.
👀 What to Watch
Investors should view this as a move to ensure operational continuity using internal talent. Monitor future announcements regarding the permanent appointment of a CEO or MD for long-term strategic direction.
IFB Industries MD Panamanna Hariharan Narayanan Resigns Effective April 1, 2026
IFB Industries Limited has announced the resignation of Mr. Panamanna Hariharan Narayanan from his position as Managing Director (Engineering Division), effective April 1, 2026. Mr. Narayanan cited personal commitments and retirement as the primary reasons for his departure after a 2.5-year tenure with the company. The resignation was formally communicated via email on March 27, 2026, and disclosed to the exchanges on March 28, 2026. Investors should note that the transition period is significant, providing the company time to find a suitable successor.
Key Highlights
Mr. Panamanna Hariharan Narayanan to step down as Managing Director on April 1, 2026.
The resignation concludes a 2.5-year tenure leading the company's Engineering Division.
Departure is attributed to personal commitments and retirement rather than operational issues.
The company has approximately one year to manage the leadership transition for the division.
👀 What to Watch
Investors should monitor future filings for the appointment of a new Managing Director to ensure leadership continuity. No immediate action is required as the resignation is planned well in advance.
IFB Industries Appoints Veteran Arup Das as Executive Director in Interim Role
IFB Industries Limited has appointed Mr. Arup Das as an Additional Director in the category of Executive Director, effective March 28, 2026. Mr. Das is a company veteran with 34 years of experience at IFB and over 38 years of total professional experience in marketing, sales, and general management. This appointment is for an interim period until a new Chief Executive Officer or Managing Director is appointed. His current role as President of M&A and New Projects suggests he will provide strategic continuity during this leadership transition.
Key Highlights
Mr. Arup Das appointed as Executive Director effective March 28, 2026
The appointee has 34 years of tenure at IFB and over 38 years of total industry experience
Appointment is for an interim period until a permanent CEO or Managing Director is selected
Mr. Das currently serves as President of M&A and New Projects at the company
👀 What to Watch
Investors should monitor the company's progress in appointing a permanent CEO or Managing Director to ensure long-term leadership stability. The interim appointment of a long-term insider provides operational continuity in the short term.
Panacea Biotec Faces ₹9.38 Cr Tax Penalty Demand as CIT(A) Dismisses Appeals
Panacea Biotec Limited has received an adverse ruling from the Commissioner of Income Tax (Appeals), New Delhi, which dismissed the company's appeals against penalty orders. These orders pertain to alleged under-reporting of income for the Assessment Years 2017-18, 2020-21, and 2021-22. The aggregate demand resulting from these penalties stands at approximately ₹9.38 crore. While the company intends to challenge this order before a higher appellate authority, the dismissal of the current appeal reinforces the immediate tax liability risk.
Key Highlights
CIT(A) dismissed three appeals against penalty orders issued by the Assistant Commissioner of Income Tax.
The total aggregate tax demand involved in the litigation is approximately ₹9.38 crore.
The penalties relate to alleged under-reporting of income for AY 2017-18, 2020-21, and 2021-22.
Panacea Biotec plans to file a further appeal with the next appellate authority to contest the demand.
Management currently maintains that the demand will not have a relevant impact on operations or financial activities.
👀 What to Watch
Investors should monitor the progress of the next appeal as a final unfavorable outcome would necessitate a ₹9.38 crore cash outflow. The news is likely to weigh slightly on the stock price in the short term due to the legal setback.
Triveni Turbine Shareholders Approve Re-appointment of Nikhil Sawhney as MD with 84.9% Majority
Triveni Turbine Limited has successfully passed a special resolution via postal ballot for the re-appointment of Mr. Nikhil Sawhney as Managing Director. The resolution received 84.91% approval from the total votes polled, ensuring leadership continuity for the company. However, the results revealed significant dissent from public institutional investors, with 40.53% of their votes cast against the proposal. Despite this institutional resistance, the resolution met the requisite majority threshold for a special resolution.
Key Highlights
Special resolution for re-appointment of Nikhil Sawhney as MD passed with 84.91% assent.
Promoter group provided full support with 100% of their 17.75 crore shares voting in favor.
Public institutional investors showed notable resistance, with 40.53% (4.27 crore votes) dissenting.
Total valid votes polled were 28.29 crore, representing approximately 89% of the total paid-up share capital.
The resolution was deemed passed on March 26, 2026, following the conclusion of the e-voting period.
👀 What to Watch
Investors should view this as a positive for leadership stability, though the high institutional dissent suggests a need to monitor future governance and compensation disclosures.
BirlaNu Board Approves Increase in Corporate Guarantee Limit to Euro 55 Million
BirlaNu Limited has granted in-principle approval to enhance its corporate guarantee limit for its wholly-owned German subsidiary, BirlaNu International GmbH. The limit is being increased from Euro 45 million to Euro 55 million, an increment of Euro 10 million. This guarantee, which includes Stand-by Letters of Credit, is intended to secure existing and future loan facilities for the subsidiary and its units. The move signals continued financial backing for the company's international operations and expansion strategy.
Key Highlights
Corporate guarantee limit enhanced from Euro 45 million to Euro 55 million
Guarantee provided for BirlaNu International GmbH, Germany, a 100% subsidiary
Includes provisions for guarantees in the form of Stand-by Letters of Credit (SBLC)
Funds will secure existing and future loan facilities for the subsidiary and its units
Board meeting concluded at 3:25 PM IST on March 27, 2026
👀 What to Watch
Investors should monitor the financial health and debt-servicing capability of the German subsidiary as this increase in contingent liability ties the parent company closer to its international performance. Ensure that the additional credit headroom is being utilized for growth-oriented capital expenditure or efficient refinancing.
Biocon Appoints Shreehas Tambe as CEO & MD; Integrates Biologics and Generics Units
Biocon Limited has announced the appointment of Shreehas Tambe as CEO & Managing Director, effective April 1, 2026, alongside Kedar Upadhye as CFO. This leadership transition marks the full integration of Biocon Biologics into Biocon Limited, creating a unified global biopharma enterprise. Tambe previously led Biocon Biologics to a USD 5.5 billion valuation and successfully integrated the Viatris biosimilars acquisition. The restructured entity will focus on a combined portfolio of 12 biosimilars and 30+ generic formulations across 120+ countries.
Key Highlights
Shreehas Tambe appointed CEO & MD and Kedar Upadhye as CFO, effective April 1, 2026.
Full integration of Biocon Biologics as a wholly owned subsidiary to simplify corporate structure.
Biocon Biologics reached a valuation of USD 5.5 billion under Tambe's previous leadership.
Combined entity manages 12 commercialized biosimilars and a pipeline of 20+ biosimilar assets.
Strategic focus on high-growth areas including GLP-1 peptides, obesity, and oncology.
👀 What to Watch
Investors should view the leadership continuity and structural simplification as a positive move to drive operational efficiency. Monitor the company's ability to scale its GLP-1 and biosimilar pipeline under the new unified management.
Biocon Appoints Shreehas Tambe as CEO and Kedar Upadhye as CFO in Major Leadership Overhaul
Biocon has announced a significant leadership restructuring effective April 1, 2026, to integrate Biocon Biologics into a unified global entity. Shreehas Pradeep Tambe, currently CEO of Biocon Biologics, will take over as CEO and MD of Biocon Limited for a 5-year term, succeeding Siddharth Mittal. Kedar Narayan Upadhye, who recently led a benchmark $800 million bond issuance, has been appointed as the group CFO. This move involves the cessation of seven senior management roles as the company streamlines its organizational structure to drive global biopharma leadership.
Key Highlights
Shreehas Pradeep Tambe appointed as CEO & MD for a 5-year term starting April 1, 2026
Kedar Narayan Upadhye, who managed a $800 million bond issuance, appointed as the new CFO
Integration of Biocon Biologics leadership into the parent company to create a unified global biopharma leader
Resignation of Siddharth Mittal (CEO) and Mukesh Kamath (Interim CFO) effective March 31, 2026
Streamlining of management with the cessation of 7 senior management personnel roles
👀 What to Watch
Investors should view this as a strategic move to simplify the corporate structure and leverage the growth of the biologics business. Monitor the execution of the unified strategy and its impact on operational margins over the next few quarters.
Biocon Announces Major Leadership Overhaul; Shreehas Tambe Appointed CEO & MD
Biocon Limited is undergoing a significant organizational restructuring to integrate Biocon Biologics into a unified global entity. Shreehas Pradeep Tambe, the current CEO of Biocon Biologics, has been appointed as the CEO and Managing Director of Biocon Limited for a five-year term starting April 1, 2026. Additionally, Kedar Narayan Upadhye, who recently managed an $800 million bond issuance, will take over as the Group CFO. This transition involves the departure or reassignment of several senior management personnel, including the COO and CSO, to streamline the leadership structure.
Key Highlights
Shreehas Pradeep Tambe appointed as CEO & MD for a 5-year term effective April 1, 2026.
Kedar Narayan Upadhye appointed as CFO, bringing experience from a successful $800 million global bond issuance.
Seven senior management personnel, including the COO, CSO, and CCO, will cease their current roles as part of the integration.
The restructuring aims to create a unified 'lab to patient' global biopharmaceutical leader by merging Biocon and Biocon Biologics operations.
Outgoing CEO Siddharth Mittal and Interim CFO Mukesh Kamath will transition to other leadership roles within the Biocon Group.
👀 What to Watch
Investors should closely monitor the execution of this leadership transition and the subsequent integration of the biologics business for potential operational synergies. While the new leadership has a strong track record, the departure of multiple senior executives simultaneously warrants a cautious watch on short-term stability.
Biocon Announces Major Leadership Overhaul; Shreehas Tambe Appointed CEO & MD
Biocon Limited has announced a significant leadership restructuring effective April 1, 2026, to integrate Biocon Biologics into a unified global biopharmaceutical entity. Shreehas Pradeep Tambe, the current CEO of Biocon Biologics, will take over as CEO and MD of Biocon Limited for a five-year term, succeeding Siddharth Mittal. Additionally, Kedar Narayan Upadhye, who recently orchestrated an $800 million bond issuance for the biologics arm, has been appointed as the new CFO. This move involves streamlining the organization, resulting in the cessation of seven senior management roles at the standalone level to create a more integrated leadership structure.
Key Highlights
Shreehas Pradeep Tambe appointed as CEO & MD for a 5-year term starting April 1, 2026.
Kedar Narayan Upadhye appointed as CFO, bringing experience from a recent $800 million bond issuance.
Integration aims to unify Biocon Biologics, which reached a valuation of $5.5 billion in 2025, with the parent company.
Seven senior management personnel, including the COO and CSO, will cease their current roles as part of the organizational streamlining.
The restructuring follows the December 2025 announcement to create a unified global biopharmaceutical leader.
👀 What to Watch
Investors should view this leadership consolidation as a positive step toward operational synergy and simplified corporate structure. Monitor the transition for improvements in consolidated margins and execution of the unified global strategy.
Biocon Announces Major Leadership Overhaul; Shreehas Tambe Appointed CEO & MD
Biocon Limited is undergoing a significant management restructuring to integrate Biocon Biologics into a single unified entity, effective April 1, 2026. Shreehas Tambe, who led Biocon Biologics to a $5.5 billion valuation in 2025, will take over as CEO and MD from Siddharth Mittal. Kedar Upadhye, who recently managed an $800 million bond issuance, has been appointed as the new CFO. This move involves the cessation of seven senior management roles as the company streamlines its global biopharmaceutical operations.
Key Highlights
Shreehas Pradeep Tambe appointed as CEO & MD for a 5-year term starting April 1, 2026.
Kedar Narayan Upadhye appointed as CFO, previously instrumental in an $800 million bond issuance.
Integration aims to unify Biocon and Biocon Biologics (valued at $5.5 billion) into a single global leader.
Seven senior management personnel to step down effective March 31, 2026, as part of organizational streamlining.
Outgoing CEO Siddharth Mittal and Interim CFO Mukesh Kamath to transition into other leadership roles within the Biocon Group.
👀 What to Watch
Investors should view this consolidation as a positive step toward operational efficiency and synergy between the parent and its high-growth biologics arm. Monitor the transition for any execution risks in the newly unified organizational structure.
BIL Vyapar CoC Approves Resolution Plan Request and Evaluation Matrix
BIL Vyapar Limited, formerly known as Binani Industries, has announced the outcomes of its 6th Committee of Creditors (CoC) meeting under the Corporate Insolvency Resolution Process (CIRP). The CoC has officially approved the Request for Resolution Plan (RFRP) and the Evaluation Matrix, which are critical steps for inviting and assessing potential bidders for the company. Additionally, the committee ratified the CIRP costs and the appointment of tax consultants. This progress indicates that the insolvency process is moving toward the stage of seeking a formal resolution plan to settle outstanding debts.
Key Highlights
CoC approved the Request for Resolution Plan (RFRP) and Evaluation Matrix via e-voting concluded on March 23, 2026.
The 6th meeting of the Committee of Creditors was held on March 13, 2026, to advance the insolvency roadmap.
Ratification of CIRP costs and the appointment of Pawan Vani & Associates as Tax Consultants was finalized.
The company remains under the Corporate Insolvency Resolution Process (CIRP) as per SEBI and IBC regulations.
👀 What to Watch
Investors should remain highly cautious as equity shareholders typically face significant dilution or total loss of value during insolvency resolutions. Monitor the upcoming resolution plans to determine if any value will be preserved for minority shareholders.
Bikaji Foods Subsidiary Acquires Additional 8.59% Stake in Hazelnut Factory for ₹40 Crore
Bikaji Foods Retail Limited (BFRL), a wholly-owned subsidiary of Bikaji Foods International, has completed the second tranche of its acquisition in Hazelnut Factory Food Products Private Limited (THF). This tranche involved acquiring an 8.59% stake for ₹39.99 crore, bringing Bikaji's total aggregate shareholding in THF to 48.99%. THF is a growing F&B brand with a turnover of ₹54.31 crore in FY25, specializing in premium bakery, sweets, and café operations. The move is part of Bikaji's strategic expansion into the Quick Service Restaurant (QSR) and premium food segments.
Key Highlights
Acquired 8.59% additional stake in THF for a cash consideration of ₹39.99 crore
Total aggregate shareholding in THF increased to 48.99% with a total investment of approx. ₹101 crore
THF turnover grew from ₹39.31 crore in FY23 to ₹54.31 crore in FY25
Strategic focus on expanding the Quick Service Restaurant (QSR) vertical through a House-of-Brand strategy
THF operates cafés in Uttar Pradesh and Delhi, offering bakery, patisserie, and artisanal sweets
👀 What to Watch
Investors should monitor the integration of THF into Bikaji's retail portfolio as it represents a shift toward higher-margin premium bakery and QSR segments. The steady growth of THF's turnover suggests a successful brand that could enhance Bikaji's consolidated revenue and market presence.
Birla Corp Commissions 1.4 MT Capacity Expansion at Kundanganj; Total Capacity Reaches 21.4 MT
Birla Corporation's subsidiary, RCCPL, has successfully commissioned a 1.4 million ton (mt) third production line at its Kundanganj unit in Uttar Pradesh. This expansion, completed at an estimated cost of Rs 300 crore, increases the company's total consolidated capacity to 21.4 mt. The project is strategically positioned to serve central and eastern UP and will benefit from GST-linked investment incentives for 12 years. Additionally, the company is integrating a 5-MW solar plant to raise renewable energy consumption to 40% at the unit.
Key Highlights
Commissioned 1.4 mt additional grinding capacity at Kundanganj, UP, for approximately Rs 300 crore
Total consolidated production capacity scaled up to 21.4 mt, with a roadmap to reach 27.6 mt by 2028-29
Entitled to GST-linked investment-promotion incentives for a duration of 12 years
Installing a 5-MW solar power plant to increase renewable energy share from 30% to 40%
Strategic focus on high-growth markets in Uttar Pradesh and increased production of blended cement (PPC)
👀 What to Watch
Investors should look favorably on this capacity addition as it strengthens Birla Corp's regional leadership and provides fiscal benefits through long-term incentives. The clear roadmap to 27.6 mt capacity by 2028-29 suggests a sustained growth trajectory.
